PT Medisafe Technologies – Trademark Portfolio
Entity Type: 03
PT Medisafe Technologies holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 15 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 2 Nice Classification classes. Currently, 9 trademarks are registered and 3 are pending. Notable registered marks include ISOSENSE, CHLOROSENSE, CHLOROSENSE MICRO, CHLOROSENSE OPTIMA, and CHLOROSENSE PRECISE. The owner is based in Medan, Sumatera Utara.
Jl. Batang Kuis Gg. Tabak Rejo / PSR IX
Medan, Sumatera Utara 20367 , ID
Showing of trademarks Trademarks
Trademark Classifications
PT Medisafe Technologies's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does PT Medisafe Technologies have?
PT Medisafe Technologies has 15 U.S. trademarks filed with the USPTO. Of these, 9 registered, 3 pending, 3 abandoned.
What trademark classes does PT Medisafe Technologies file in?
PT Medisafe Technologies files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 9 (Computers & Electronics). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are PT Medisafe Technologies's most well-known trademarks?
PT Medisafe Technologies's registered trademark portfolio includes well-known marks such as ISOSENSE, CHLOROSENSE, CHLOROSENSE MICRO, CHLOROSENSE OPTIMA, and CHLOROSENSE PRECISE. These are among 9 currently registered trademarks in the portfolio.
What is PT Medisafe Technologies's trademark registration success rate?
PT Medisafe Technologies has a 75% trademark registration rate, with 9 out of 12 resolved applications resulting in successful registration. Currently, 3 applications are pending review.